ArticleFrontiers in genetics2025
Identification and validation of ubiquitination-related genes for predicting cervical cancer outcome.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Abnormalities in ubiquitination-related pathways or systems are closely associated with various cancers, including cervical cancer (CC). However, the biological function and clinical value of ubiquitination-related genes (UbLGs) in CC remain unclear. This study aimed to explore key UbLGs associated with CC, construct a prognostic model, and investigate their potential clinical and immunological significance. Methods: Differentially expressed genes (DEGs) between CC (tumor) and standard samples in self-sequencing and TCGA-GTEx-CESC datasets were identified using differential analysis. We identified overlaps between DEGs in both datasets and UbLGs, revealing key crossover genes. Subsequently, biological markers were identified via univariate Cox regression analysis and least absolute shrinkage and selection operator algorithms. After conducting independent prognostic analysis, immune infiltration analysis was performed to investigate the immune cells that differed between the two risk subgroups. Differences in immune checkpoint expression between the subgroups were analyzed. Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) was performed to confirm the expression trends of the biomarkers. Results: Differentially expressed genes related to ubiquitination were screened from the Self-seq and TCGAGTEx-CESC datasets, and five key biomarkers (MMP1, RNF2, TFRC, SPP1, and CXCL8) were identified. The risk score model constructed based on these biomarkers could effectively predict the survival rate of cervical cancer patients (AUC >0.6 for 1/3/5 years). Immune microenvironment analysis showed that 12 types of immune cells, including memory B cells and M0 macrophages, as well as four immune checkpoints, exhibited significant differences between the high-risk and low-risk groups. RT-qPCR confirmed that MMP1, TFRC, and CXCL8 were upregulated in tumor tissues. Discussion: Our study identified five ubiquitination-related biomarkers, namely, MMP1, RNF2, TFRC, SPP1, and CXCL8, which were significantly associated with CC. The validated risk model demonstrates strong predictive value for patient survival. These findings provide crucial insights into the role of ubiquitination in CC pathogenesis and offer valuable targets for advancing future research and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.